Literature DB >> 10190664

FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics.

S Pecorelli, J L Benedet, W T Creasman, J H Shepherd.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10190664     DOI： 10.1016/s0020-7292(98)00234-3

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN： 0020-7292            Impact factor:   3.561


× No keyword cloud information.
  15 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

2.  The importance of precise pT diagnosis for prognostic prediction of uterine cervical cancer--a single institutional report at a Japanese comprehensive cancer hospital.

Authors:  Norihiro Teramoto; Rieko Nishimura; Koichi Mandai; Takashi Matsumoto; Takamitsu Nogawa; Masamichi Hiura
Journal:  Virchows Arch       Date:  2009-09-24       Impact factor: 4.064

3.  Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group.

Authors:  Shogo Shigeta; Muneaki Shimada; Keita Tsuji; Tomoyuki Nagai; Yasuhito Tanase; Koji Matsuo; Shoji Kamiura; Takashi Iwata; Harushige Yokota; Mikio Mikami
Journal:  Int J Clin Oncol       Date:  2022-06-14       Impact factor: 3.850

4.  Histopathologic differences account for racial disparity in uterine cancer survival.

Authors:  David Smotkin; Nicole S Nevadunsky; Kimala Harris; Mark H Einstein; Yiting Yu; Gary L Goldberg
Journal:  Gynecol Oncol       Date:  2012-08-29       Impact factor: 5.482

5.  The role and timing of palliative medicine consultation for women with gynecologic malignancies: association with end of life interventions and direct hospital costs.

Authors:  Nicole S Nevadunsky; Sharon Gordon; Lori Spoozak; Anne Van Arsdale; Yijuan Hou; Merieme Klobocista; Serife Eti; Bruce Rapkin; Gary L Goldberg
Journal:  Gynecol Oncol       Date:  2013-10-29       Impact factor: 5.482

6.  Metformin use and endometrial cancer survival.

Authors:  Nicole S Nevadunsky; Anne Van Arsdale; Howard D Strickler; Alyson Moadel; Gurpreet Kaur; Marina Frimer; Erin Conroy; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2013-11-02       Impact factor: 5.482

7.  Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer.

Authors:  I Meinhold-Heerlein; C Fotopoulou; P Harter; C Kurzeder; A Mustea; P Wimberger; S Hauptmann; J Sehouli
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-10       Impact factor: 2.915

8.  Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway.

Authors:  S Battersby; K J Sales; A R Williams; R A Anderson; S Gardner; H N Jabbour
Journal:  Hum Reprod       Date:  2006-08-12       Impact factor: 6.918

9.  Can CA-125 predict lymph node metastasis in epithelial ovarian cancers in Turkish population?

Authors:  Sinem Sudolmuş; Nadiye Köroğlu; Gökhan Yıldırım; Volkan Ülker; Ahmet Gülkılık; Ramazan Dansuk
Journal:  Dis Markers       Date:  2014-03-25       Impact factor: 3.434

10.  Involvements of Estrogen Receptor, Proliferating Cell Nuclear Antigen and p53 in Endometrial Adenocarcinoma Development in Donryu Rats.

Authors:  Midori Yoshida; Shin-Ichi Katsuda; Akihiko Maekawa
Journal:  J Toxicol Pathol       Date:  2012-12-20       Impact factor: 1.628
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.